What is ReachBio?
ReachBio Research Labs operates as a contract research organization, specializing in primary cell biology-based services and products tailored for the drug development and life science research communities globally. The company's core competencies lie in various aspects of primary cell biology, with a particular emphasis on blood and bone marrow primary cell systems. ReachBio collaborates with clients across the spectrum of basic research to pre-clinical and clinical drug development, addressing critical interests in hematology, immunology, toxicology, hematological diseases, and immuno-oncology.
How much funding has ReachBio raised?
ReachBio has raised a total of $187K across 1 funding round:
Debt
$187K
Debt (2021): $187K with participation from PPP
Key Investors in ReachBio
PPP
Public-Private Partnership
What's next for ReachBio?
The substantial late-stage funding positions ReachBio for accelerated growth and expanded operational capacity. This capital infusion is expected to fuel strategic initiatives, potentially including the enhancement of its service offerings, expansion into new therapeutic areas, and further development of its proprietary product lines. The company's focus on critical areas of drug development suggests a trajectory aimed at solidifying its role as a key partner for pharmaceutical and biotechnology firms navigating complex research challenges.
See full ReachBio company page
